Abstract:Objectives: To establish a cell line stably expressing the transient receptor potential melastatin 2 (TRPM2) channel for screening TRPM2 inhibitors based on PiggyBac transposition system. Methods: A plasmid PiggyBac-human TRPM2 (pPB-hTRPM2) eukaryotic expression vector was constructed using PiggyBac transposition system. The plasmid and a helper plasmid were co-transfected into HEK293T cells to express TRPM2, which was identified by fluorescence and patch-clamp assays. The high throughput screening performance was assessed with the Z ´ factor. Calcium imaging and patch clamp techniques were employed to assess the initial activity of eleven compound molecules, confirming the inhibitory effects of the primary molecules on TRPM2. The protective effect of the screened compounds on damaged cells was validated using the oxygen-glucose deprivation/reperfusion (OGD/R) injury model and CCK-8 kit. The level of cellular reactive oxygen species (ROS) was detected by flow cytometry. The neuroprotective effects of the compounds were evaluated using a transient middle cerebral artery occlusion (tMCAO) mouse model. Results: The HEK293T cells transfected with pPB-hTRPM2-EGFP showed high TRPM2 expression. Puromycin-resistant cells, selected through screening, exhibited robust fluorescence. Whole-cell patch results revealed that induced cells displayed classical TRPM2 current characteristics comparable to the control group, showing no significant differences (P>0.05). With a Z ´ factor of 0.5416 in calcium imaging, the model demonstrated suitability for high-throughput screening of TRPM2 inhibitors. Calcium imaging and electrophysiological experiments indicated that compound 6 significantly inhibited the TRPM2 channel. Further experiments showed that 1.0 μmol/L of compound 6 enhanced cell viability (P<0.05) and reduced the level of ROS (P<0.05) of SH-SY5Y under OGD/R injury. 0.3 and 1.0 mg/kg of compound 6 reduced the cerebral infarction volume in tMCAO mice (both P<0.05). Conclusions: A stable TRPM2 gene expressing cell line has been successfully established using PiggyBac gene editing in this study. TRPM2 channel inhibitors were screened through calcium imaging and patch clamp techniques, and an inhibitor compound 6 was identified. This compound can alleviate cell damage after OGD/R by reducing cellular ROS levels and has a protective effect against cerebral ischemia-reperfusion injury in mice.

[Construction of HEK293 Cell Lines Expressing Hcyslt₂ Receptor and Its Application in Screening of Antagonists].

[Method for screening cysteinyl leukotriene receptor 2 antagonists and preliminary screening of compounds].

Structure-based drug design using GPCR homology modeling: toward the discovery of novel selective CysLT2 antagonists.

Identification of a HEK-293 Cell Line Containing Stably-Transfected H3 R Gene and Screening for Novel Non-Imidazole Histamine H3 Receptor Antagonists

Establishment of a stable cell line expressing "toxic" transient receptor potential A1 channel

A High-Throughput Screening System for G-protein-coupled Receptors Using Β-Lactamase Enzyme Complementation Technology.

Screening of Thiourea Derivatives and Carbonyl-2-aminothiazole Derivatives for Potential CCR4 Antagonists Using Capillary Zone Electrophoresis

Cell Active and Functionally-Relevant Small-Molecule Agonists of Calcitonin Receptor.

Functional Identification of the Stable Transfection C5ar Cell Line Molt-4

[Construction of HEK293T cell line stably expressing TRPM2 channel based on PiggyBac transposition system and its application in drug screening for cerebral ischemia and other diseases]

[Electrophysiology of two human hyperpolarization activated cyclic nucleotide-gated potassium channels expressed in HEK293 cells].

Screening of Chemokine Receptor CCR4 Antagonists by Capillary Zone Electrophoresis

[Construction and Expression of the Eukaryotic Expression Vector Containing Human Soluble Transforming Growth Factor Beta Receptor II].

Pharmacophore identification, synthesis, and biological evaluation of carboxylated chalcone derivatives as CysLT1 antagonists.

[Coexpression of PXRLBD with SRC88 and Construction of Equilibrium Dialysis Model of Screening PXR Ligands].

Establishment of a human cell line with a surface display system for screening and optimizing Na+-taurocholate cotransporting polypeptide-binding peptides

[Establishment of a Cell Based High Throughput Screening Model for Transient Receptor Potential V3 Modulators].

[Preparation and Identification of Polyclonal Antibody Against Cysteinyl Leukotriene Receptor 2].

CCR4 Expressing Cells Cultured Adherently on a Capillary Wall and Formaldehyde Fixed As the Stationary Phase for Ligand Screening by ACE

Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators

Site-specific immobilization of Cysteinyl leukotriene receptor 1 through enzymatic DNA-protein conjugation strategy for lead screening